Join
Live feed
·
PRReleasevia Quantisnow
Precision BioSciences Inc. logo

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

ByQuantisnow·Wall Street's wire, on your screen.
DTIL· Precision BioSciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DTIL (Precision BioSciences Inc.) and more on Quantisnow.